Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Otwock – page 3

61 clinical trials in Otwock, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Otwock at a glance
61
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

61 trials in Otwock

Open in trial search

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Pfizer Inc.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Pulmonary hypertension

Not recruiting

Study on the Effects of Mosliciguat for Patients with Pulmonary Hypertension Linked to Interstitial Lung Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mosliciguat
  • Sponsor:Pulmovant Inc.

Anaplastic lymphoma kinase gene mutation

Not recruiting

Study Comparing Alectinib and Crizotinib for Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing the Effects and Safety of FYB206 and Pembrolizumab with Chemotherapy in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Formycon AG

Hormone-refractory prostate cancer

Not recruiting

Study of Cabozantinib and Atezolizumab Compared to Hormonal Therapy in Adults with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Exelixis Inc.

Small cell lung cancer+1

Not recruiting

Study of Atezolizumab, Carboplatin, and Etoposide with or Without Tiragolumab for Patients with Untreated Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Pulmonary arterial hypertension

Not recruiting

Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Pulmonary arterial hypertension

Not recruiting

Long-term Study of Sotatercept for Adults with Pulmonary Arterial Hypertension (PAH)

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Non-small cell lung cancer

Not recruiting

Study of Cemiplimab and Chemotherapy Combination for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Renal cell carcinoma

Not recruiting

Study on Atezolizumab and Cabozantinib for Patients with Advanced Renal Cell Carcinoma After Tumor Progression Post-Immune Checkpoint Inhibitor Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Effectiveness of Cibotercept (KER-012) with Other Drugs for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cibotercept
  • Sponsor:Keros Therapeutics Inc.

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Otwock

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on targeted therapies for various types of cancer, including breast, lung, and colorectal malignancies.

  • Advanced breast cancer treatments with novel drug combinations
  • Non-small cell lung cancer therapeutic approaches
  • Colorectal cancer targeted interventions

Studies evaluating breakthrough treatments for patients with metastatic disease and specific genetic mutations.

02 Pulmonary Medicine

Research focusing on treating pulmonary hypertension and related conditions through innovative therapeutic approaches.

  • Pulmonary arterial hypertension treatments
  • Interstitial lung disease interventions
  • Novel inhaled therapies evaluation

Clinical investigations exploring new treatment options to improve patient outcomes in severe respiratory conditions.

03 Precision Medicine

Advanced trials implementing personalized treatment approaches based on specific genetic markers and patient characteristics.

  • HER2-targeted therapies
  • KRAS mutation-specific treatments
  • Immunotherapy combinations

Studies focused on matching patients with optimal treatments based on their unique genetic profiles.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.